

## Supplementary Material - Table

**Table.** Evolution of the quality of life, treatment, pulmonary function, and laboratory tests. Bronchial thermoplasty was performed between April 2015 and May 2015.

	May 2013	June 2015	December 2017	March 2019
<b>Quality of Life</b>				
• Emergency room visits by year	12-15	-	-	-
• Hospital admissions by year	7-8	-	-	-
• NYHA functional class	III-IV	I	II	II
• ACT	8	20	18	17
<b>Treatment</b>				
• Budesonide/formoterol 160/4.5 µg	2 inhalations twice daily	2 inhalation twice daily	-	-
• Tiotropium bromide 2.5 µg	2 inhalations once daily	2 inhalations once daily	2 inhalations once daily	2 inhalations once daily
• Montelukast 10 mg	1	1	1	1
• Aerosol therapy with budesonide/ipratropium/ salbutamol/hypertonic saline	Frequent	-	-	-
• Chest physiotherapy	Frequent	-	-	-
• Long-term domiciliary oxygen therapy	At 2 liters/night	-	-	-
• Prednisone, mg/d	30	-	20	40-50
• Roflumilast, µg/d	-	-	-	500
• Fluticasone/formoterol 250/10 µg	-	-	2 inhalations twice daily	2 inhalations twice daily
<b>Pulmonary Function</b>				
• FVC, mL (%)	2 360 (70)	3 830 (112)	1 490 (44)	2 050 (60)
• FEV1, mL (%)	1 100 (37)	2 800 (94)	940 (32)	1 210 (41)
• FEV1/FVC, %	46	73	63	58
• FeNO, ppb	58	47	53	64
• BMI, kg/m <sup>2</sup>	42	23	27	33
<b>Laboratory Tests</b>				
• Serum tryptase, µg/L	4.8	5.1	4.2	3.9
• Blood eosinophils, cells/µL (%)	210 (2.9)	130 (1.5)	240 (2.6)	100 (2.8)
• Serum total IgE, IU/mL	644	825	387	280

Abbreviations: NYHA, New York Heart Association; ACT, Asthma Control Test (ACT < 20, uncontrolled asthma; and ACT 20-25, controlled asthma); FVC, Forced vital capacity; FEV1, Forced expiratory volumen in 1 second; FeNO, Fractional exhaled nitric oxide (normal to 50); BMI, Body mass index (BMI >30, obese; BMI 26-30, overweight; BMI 20-25, healthy weight).